62 results
8-K
EX-99.1
NKTX
Nkarta Inc
9 May 24
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
4:04pm
, and investments in marketable securities of $450.0 million as of March 31, 2024.
Research and development (R&D) expenses were $25.2 million for the first … expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income, net:
Interest income
Other
8-K
EX-99.1
qcgbx giv7gz
21 Mar 24
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:15pm
8-K
EX-99.1
q6n1gr fd
9 Nov 23
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:06pm
8-K
EX-99.1
o0v1fvsuzirc9pt2f1
10 Aug 23
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
7:05am
8-K
EX-99.1
7kxll4
11 May 23
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
4:06pm
PRE 14A
2dp4e3c4rw
14 Apr 23
Preliminary proxy
5:00pm
8-K
EX-99.1
r939tnh9iv4o1g6lg1
9 Nov 22
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:03pm
8-K
EX-99.1
as8qt7q vcrodw4ex
11 Aug 22
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:10pm
8-K
j3mzbnmtm3 0t
16 May 22
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
4:09pm
8-K
EX-99.1
af2bqw2eosxq u29sue2
16 May 22
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
4:09pm